{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:37:23Z","timestamp":1795228643200,"version":"4.10.3"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>The use of a watch-and-wait management strategy after a complete clinical response to neoadjuvant therapy for rectal cancer is increasing. However, insights into implementation, treatments, and outcomes on a national level in the United States are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To investigate and report on watch-and-wait management practices and outcomes in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Multicenter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Patients with stage II or III rectal cancer who underwent intentional watch-and-wait management between January 2015 and August 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>Patient and tumor characteristics, neoadjuvant treatment and response, local cancer regrowth and metastasis, salvage surgery, overall survival, and disease-specific survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Among 545 patients from 33 centers, follow-up was 21 months (range, 9\u201337). Total neoadjuvant therapy or other types of neoadjuvant therapy were used in 395 (72%) and 150 (28%) patients, respectively. The estimated 3-year local regrowth rate was 23.8% (95% CI, 19.1%\u201329.4%). Patients with local regrowth had higher distant metastases incidence (14.2% vs 3.5%, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). Salvage surgery was performed in 74 of 84 patients (88%) with local regrowth and included rectal resection in 66 patients (89%) and local excision in 8 (11%). Of 64 salvage resections with known pathology results, 58 (91%) were margin-negative. Overall, 3-year overall survival was 94.8% (95% CI, 90.5%\u201397.2%) and 3-year disease-specific survival was 96.2% (95% CI, 91.8%\u201398.2%). Patients with and without local regrowth exhibited 3-year overall survival of 83.6% (95% CI, 68.4%\u201391.9%) and 97.7% (95% CI, 93.3%\u201399.2%), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Retrospective study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>This multicenter study indicates that the watch-and-wait approach for locally advanced rectal cancer is feasible with acceptable outcomes across a variety of geographical regions and practice settings in the United States. Local regrowth and distant metastasis rates were within published norms and salvage surgery proved effective. See <jats:bold>Video Abstract<\/jats:bold>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MANEJO DE ESPERA Y OBSERVACI\u00d3N DEL C\u00c1NCER RECTAL: EXPERIENCIA DE 545 PACIENTES DEL GRUPO DE INVESTIGACI\u00d3N DEL C\u00c1NCER RECTAL DE EE UU<\/jats:title>\n            <jats:p>\n                                 <jats:bold>ANTECEDENTES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>El uso de una estrategia de manejo de observaci\u00f3n y espera despu\u00e9s de una respuesta cl\u00ednica completa a la terapia neoadyuvante para el c\u00e1ncer de recto est\u00e1 aumentando. Sin embargo, los conocimientos sobre la implementaci\u00f3n, los tratamientos y los resultados, a nivel nacional de los Estados Unidos, son limitados.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>OBJETIVO:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Investigar e informar sobre las pr\u00e1cticas y los resultados del manejo de observaci\u00f3n y espera en los EE. UU.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>DISE\u00d1O:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Estudio retrospectivo.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>ESCENARIO:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Multic\u00e9ntrico.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>PACIENTES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Pacientes con c\u00e1ncer de recto en estadio II o III que se sometieron a un manejo de observaci\u00f3n y espera intencional entre enero de 2015 y agosto de 2022.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>PRINCIPALES MEDIDAS DE RESULTADOS:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Caracter\u00edsticas del paciente y del tumor, tratamiento neoadyuvante y respuesta, recrecimiento local del c\u00e1ncer y met\u00e1stasis, cirug\u00eda de rescate, supervivencia general y espec\u00edfica de la enfermedad.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>RESULTADOS:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Entre 545 pacientes de 33 centros, el seguimiento fue de 21 meses (rango, 9-37). Se utiliz\u00f3 terapia neoadyuvante total u otros tipos de neoadyuvancia en 395 (72%) y 150 (28%) de los pacientes, respectivamente. La tasa estimada de recrecimiento local a 3 a\u00f1os fue del 23,8% (IC del 95%: 19,1-29,4%). Los pacientes con recrecimiento local tuvieron una mayor incidencia de met\u00e1stasis a distancia (14,2% frente a 3,5%, p &lt; 0,001). Se realiz\u00f3 cirug\u00eda de rescate en 74\/84 (88%) pacientes con recrecimiento local e incluy\u00f3 resecci\u00f3n rectal en 66 (89%) y escisi\u00f3n local en 8 (11%). De 64 resecciones de rescate con resultados patol\u00f3gicos conocidos, 58 (91%) fueron m\u00e1rgenes negativos. En general, la supervivencia global a los 3 a\u00f1os fue del 94,8 % (IC del 95 %: 90,5-97,2 %) y la supervivencia espec\u00edfica de la enfermedad a los 3 a\u00f1os del 96,2 % (IC del 95 %: 91,8-98,2 %). Los pacientes con y sin recrecimiento local mostraron una supervivencia global a los 3 a\u00f1os del 83,6 % (IC del 95 %: 68,4-91,9 %) y del 97,7 % (IC del 95 %: 93,3-99,2 %), respectivamente.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>LIMITACIONES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Estudio retrospectivo.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>CONCLUSI\u00d3N:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Este estudio multic\u00e9ntrico indica que el enfoque de observaci\u00f3n y espera para el c\u00e1ncer rectal localmente avanzado es factible con resultados aceptables en una variedad de regiones geogr\u00e1ficas y entornos de pr\u00e1ctica en los EE. UU. Las tasas de recrecimiento local y met\u00e1stasis a distancia estuvieron dentro de las normas publicadas y la cirug\u00eda de rescate result\u00f3 eficaz. <jats:italic toggle=\"yes\">(Traducci\u00f3n\u2014Dr Yolanda Colorado<\/jats:italic>)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dcr.0000000000003586","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:02:23Z","timestamp":1730984543000},"page":"180-189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Rectal Cancer Watch-and-Wait Management: Experience of 545 Patients From the US Rectal Cancer Research Group"],"prefix":"10.1097","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-4255","authenticated-orcid":false,"given":"Samuel H.","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Widmar","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.T.","family":"Monson","sequence":"additional","affiliation":[{"name":"Northwell Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal J.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arden M.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon D.","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the US Rectal Cancer Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"R1-20250123","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R2-20250123","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/BF02239429","article-title":"Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.","volume":"41","author":"Habr-Gama","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"R3-20250123","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"R4-20250123","first-page":"18","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer 2023 supplement.","volume":"67","author":"Langenfeld","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"R5-20250123","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"R6-20250123","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R7-20250123","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/DCR.0000000000002654","article-title":"Circumferential resection margin as predictor of nonclinical complete response in nonoperative management of rectal cancer.","volume":"66","author":"Chin","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"R8-20250123","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/SLA.0000000000002761","article-title":"Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis.","volume":"268","author":"Dattani","year":"2018","journal-title":"Ann Surg"},{"key":"R9-20250123","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"R10-20250123","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/DCR.0000000000001338","article-title":"Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!","volume":"62","author":"Habr-Gama","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"R11-20250123","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/DCR.0000000000002122","article-title":"Organ preservation in patients with rectal cancer treated with total neoadjuvant therapy.","volume":"64","author":"Jimenez-Rodriguez","year":"2021","journal-title":"Dis Colon Rectum"},{"key":"R12-20250123","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/DCR.0000000000002290","article-title":"Total neoadjuvant therapy significantly increases complete clinical response.","volume":"66","author":"Rettig","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"R13-20250123","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(20)30557-X","article-title":"Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.","volume":"22","author":"Fernandez","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20250123","doi-asserted-by":"crossref","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy.","volume":"5","author":"Smith","year":"2019","journal-title":"JAMA Oncol"},{"key":"R15-20250123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/DCR.0000000000002494","article-title":"The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database.","volume":"66","author":"Fernandez","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"R16-20250123","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R17-20250123","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/DCR.0000000000002245","article-title":"Rectal cancer: clinical and molecular predictors of a complete response to total neoadjuvant therapy.","volume":"66","author":"Chapman","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"R18-20250123","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2023.4845","article-title":"Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020.","volume":"10","author":"Loria","year":"2024","journal-title":"JAMA Oncol"},{"key":"R19-20250123","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1245\/s10434-017-5841-3","article-title":"Nonoperative management or \u2018watch and wait\u2019 for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal.","volume":"24","author":"Sammour","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R20-20250123","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20250123","first-page":"e504","article-title":"Rectal cancer watch & wait strategy: the U.S. Rectal Cancer Research Group experience with 545 patients [ASCRS abstract T103].","volume":"67","author":"Lai","year":"2024","journal-title":"Dis Colon Rectum"}],"container-title":["Diseases of the Colon &amp; Rectum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:00:39Z","timestamp":1737673239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dcr.0000000000003586","relation":{},"ISSN":["0012-3706","1530-0358"],"issn-type":[{"value":"0012-3706","type":"print"},{"value":"1530-0358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}